Sen. Cruz Introduces the RESULT Act to Fast-Track FDA Approval for Drugs Sold in Other Countries
This bill is currently in the early stages of the legislative process after being sent to the Senate Committee on Health, Education, Labor, and Pensions for review. It is actively moving through the system, but no further hearings or votes have been scheduled at this time.
This bill faces a difficult path because it significantly changes how the government checks drug safety, which many lawmakers are hesitant to do without more oversight.
This bill’s path across every version that has carried it.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
FDA staff would face significant new workload pressures from the 30-day review deadline, which is far shorter than standard review timelines. They would also need to process foreign regulatory dossiers and negotiate labeling within that compressed window. The bill also introduces congressional override of FDA decisions, which could undermine the agency's scientific independence and create tension for career reviewers.
“the Secretary and the sponsor of the covered product shall expeditiously negotiate and finalize the form and content of the labeling for a covered product for which reciprocal marketing approval is to be granted”
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Senator Ted Cruz and Representative Chip Roy have reintroduced the RESULT Act, which would enable U.S. citizens to access medicines approved in other countries but not yet by the FDA. The bill mandates a 30-day review window and allows for reciprocal approval from trusted regulatory bodies.
The FDA is exploring new mechanisms for expediting drug approval review times, including the Commissioner's National Priority Voucher and reciprocal approval pathways outlined in the RESULT Act. These changes aim to address unmet public health needs and increase domestic manufacturing.
The Reciprocity Ensures Streamlined Use of Lifesaving Treatments (RESULT) Act seeks to amend the Federal Food, Drug, and Cosmetic Act. It establishes a system for reciprocal marketing approval of products legally marketed in the UK, EU, Israel, Australia, Canada, and Japan.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
Analysis generated by AI. Always verify with official sources.